Structural analysis of the pyroglutamate-modified isoform of the Alzheimer's disease-related amyloid-β using NMR spectroscopy

Journal of Peptide Science

Volumn 18, Issue 11, 2012, Pages 691-695

  Sun, Na ^a   Hartmann, Rudolf ^a   Lecher, Justin ^a   Stoldt, Matthias ^a,b   Funke, Susanne Aileen ^a   Gremer, Lothar ^a   Ludwig, Hans Henning ^c   Demuth, Hans Ulrich ^c   Kleinschmidt, Martin ^c   Willbold, Dieter ^a,b  

^a FORSCHUNGSZENTRUM JÜLICH   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c PROBIODRUG AG   (Germany)

Author keywords

helical structure; Aggregation; Alzheimer's disease; Membrane mimicking solvent; TFE

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[3-40]; GLYCOPROTEIN; PYROGLUTAMIC ACID; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AQUEOUS SOLUTION; ARTICLE; BETA SHEET; BRAIN; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEAR OVERHAUSER EFFECT; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECONDARY STRUCTURE; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; PROTON NUCLEAR MAGNETIC RESONANCE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN ISOFORMS; PYRROLIDONECARBOXYLIC ACID;

EID: 84867898641     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.2456     Document Type: Article

References (34)

1. Iversen LL, Mortishire-Smith RJ, Pollack SJ, Shearman MS. The toxicity in vitro of beta-amyloid protein. Biochem. J. 1995; 311(Pt 1): 1-16.
2. Haass C, Selkoe DJ. Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell 1993; 75: 1039-1042.
3. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Muller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987; 325: 733-736.
4. Weidemann A, Konig G, Bunke D, Fischer P, Salbaum JM, Masters CL, Beyreuther K. Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell 1989; 57: 115-126.
5. Wirths O, Bethge T, Marcello A, Harmeier A, Jawhar S, Lucassen PJ, Multhaup G, Brody DL, Esparza T, Ingelsson M, Kalimo H, Lannfelt L, Bayer TA. Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. J. Neural Transm. 2010; 117: 85-96.
6. Schilling S, Hoffmann T, Manhart S, Hoffmann M, Demuth HU. Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. FEBS Lett. 2004; 563: 191-196.
7. Cynis H, Rahfeld JU, Stephan A, Kehlen A, Koch B, Wermann M, Demuth HU, Schilling S. Isolation of an isoenzyme of human glutaminyl cyclase: retention in the Golgi complex suggests involvement in the protein maturation machinery. J. Mol. Biol. 2008; 379: 966-980.
8. Cummins PM, O'Connor B. Pyroglutamyl peptidase: an overview of the three known enzymatic forms. Biochim. Biophys. Acta 1998; 1429: 1-17.
9. Barrow CJ, He WL. The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta. Biochemistry 1999; 38: 10871-10877.
10. D'Arrigo C, Tabaton M, Perico A. N-terminal truncated pyroglutamyl beta amyloid peptide Abetapy3-42 shows a faster aggregation kinetics than the full-length Abeta1-42. Biopolymers 2009; 91: 861-873.
11. Schlenzig D, Manhart S, Cinar Y, Kleinschmidt M, Hause G, Willbold D, Funke SA, Schilling S, Demuth HU. Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides. Biochemistry 2009; 48: 7072-7078.
12. Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y and Kawashima S. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron 1995; 14: 457-466.
13. Ambroggio EE, Kim DH, Separovic F, Barrow CJ, Barnham KJ, Bagatolli LA, Fidelio GD. Surface behavior and lipid interaction of Alzheimer beta-amyloid peptide 1-42: a membrane-disrupting peptide. Biophys. J. 2005; 88: 2706-2713.
14. Bokvist M, Lindstrom F, Watts A and Grobner G. Two types of Alzheimer's beta-amyloid (1-40) peptide membrane interactions: aggregation preventing transmembrane anchoring versus accelerated surface fibril formation. J. Mol. Biol. 2004; 335: 1039-1049.
15. Durell SR, Guy HR, Arispe N, Rojas E, Pollard HB. Theoretical models of the ion channel structure of amyloid beta-protein. Biophys. J. 1994; 67: 2137-2145.
16. Mandal PK, Pettegrew JW. Alzheimer's disease: soluble oligomeric Abeta(1-40) peptide in membrane mimic environment from solution NMR and circular dichroism studies. Neurochem. Res. 2004; 29: 2267-2272.
17. Coles M, Bicknell W, Watson AA, Fairlie DP, Craik DJ. Solution structure of amyloid beta-peptide(1-40) in a water-micelle environment. Is the membrane-spanning domain where we think it is? Biochemistry 1998; 37: 11064-11077.
18. Shao H, Jao S, Ma K, Zagorski MG. Solution structures of micelle-bound amyloid beta-(1-40) and beta-(1-42) peptides of Alzheimer's disease. J. Mol. Biol. 1999; 285: 755-773.
19. Sticht H, Bayer P, Willbold D, Dames S, Hilbich C, Beyreuther K, Frank RW, Rosch P. Structure of amyloid A4-(1-40)-peptide of Alzheimer's disease. Eur. J. Biochem. 1995; 233: 293-298.
20. Crescenzi O, Tomaselli S, Guerrini R, Salvadori S, D'Ursi AM, Temussi PA, Picone D. Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain. Eur. J. Biochem. 2002; 269: 5642-5648.
21. Rodziewicz-Motowidlo S, Juszczyk P, Kolodziejczyk AS, Sikorska E, Skwierawska A, Oleszczuk M, Grzonka Z. Conformational solution studies of the SDS micelle-bound 11-28 fragment of two Alzheimer's beta-amyloid variants (E22K and A21G) using CD, NMR, and MD techniques. Biopolymers 2007; 87: 23-39.
22. Nelson JW, Kallenbach NR. Stabilization of the ribonuclease S-peptide alpha-helix by trifluoroethanol. Proteins 1986; 1: 211-217.
23. Sonnichsen FD, Van Eyk JE, Hodges RS, Sykes BD. Effect of trifluoroethanol on protein secondary structure: an NMR and CD study using a synthetic actin peptide. Biochemistry 1992; 31: 8790-8798.
24. Barrow CJ, Zagorski MG. Solution structures of beta peptide and its constituent fragments: relation to amyloid deposition. Science 1991; 253: 179-182.
25. Wüthrich K. NMR of Proteins and Nucleic Acids. John Wiley & Sons: New York, 1986.
26. Schwarzinger S, Kroon GJ, Foss TR, Wright PE, Dyson HJ. Random coil chemical shifts in acidic 8M urea: implementation of random coil shift data in NMRView. J. Biomol. NMR 2000; 18: 43-48.
27. Schwarzinger S, Kroon GJ, Foss TR, Chung J, Wright PE and Dyson HJ. Sequence-dependent correction of random coil NMR chemical shifts. J. Am. Chem. Soc. 2001; 123: 2970-2978.
28. He W, Barrow CJ. The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta. Biochemistry 1999; 38: 10871-10877.
29. Schilling S, Lauber T, Schaupp M, Manhart S, Scheel E, Bohm G, Demuth HU. On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry 2006; 45: 12393-12399.
30. Bax A, Davis DG. Practical aspects of two-dimensional transverse NOE spectroscopy. J. Magn. Reson. 1985; 63: 207-213.
31. Jeener J, Meier BH, Bachmann P, Ernst RR. Investigation of exchange processes by 2-dimensional NMR-spectroscopy. J. Chem. Phys. 1979; 71: 4546-4553.
32. 1H spin-spin coupling constants in proteins. Biochem. Biophys. Res. Commun. 1983; 113: 967-974.
33. Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 1995; 6: 277-293.
34. Vranken WF, Boucher W, Stevens TJ, Fogh RH, Pajon A, Llinas M, Ulrich EL, Markley JL, Ionides J, Laue ED. The CCPN data model for NMR spectroscopy: development of a software pipeline. Proteins 2005; 59: 687-696.